Mitigating Severe Ribociclib‐Hepatotoxicity With Corticosteroids
Case Reports in Oncological Medicine · 2026-01 · 2026 (1)
DOI: 10.1155/crom/4222126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Case Reports in Oncological Medicine, online erschienen am 24.04.2026. Verfasst von Julie Williamson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA, utah.edu. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ribociclib adds progression‐free survival and overall survival benefit in combination with endocrine therapy for first‐line treatment of advanced HR+ HER2− breast cancer; however, it comes with a risk of hepatotoxicity. There is guidance for monitoring liver function and holding the medication if hepatotoxicity arises. However, there is minimal guidance for management if withholding the medication alone is insufficient. We present a case of a woman with de novo metastatic HR+ HER2− breast cancer who developed grade 2 AST and ALT elevation after two cycles of ribociclib and anastrozole, which progressed over several weeks to Grade 4 hepatotoxicity despite holding the medication. Extensive evaluation revealed drug‐induced liver injury from ribociclib as the cause. Ultimately, a long course of corticosteroids was initiated with remarkable response and resolution of transaminitis. An empiric trial of corticosteroids should be considered for patients with severe ongoing hepatotoxicity from CDK4/6 inhibitors despite cessation of the drug.
Autor:innen und Institutionen
- Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA, utah.edu.
- Department of Pathology, University of Utah, Salt Lake City, Utah, USA, utah.edu.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA, utah.edu.
ORCID-Profile: Julie Williamson, Maria Pletneva, Rebecca G Kim
Zitieren
APA
Williamson, J., Pletneva, M., Kim, R. G., & Bhatia, R. (2026). Mitigating Severe Ribociclib‐Hepatotoxicity With Corticosteroids. Case Reports in Oncological Medicine, 2026(1). https://doi.org/10.1155/crom/4222126
Vancouver
Williamson J, Pletneva M, Kim RG, Bhatia R. Mitigating Severe Ribociclib‐Hepatotoxicity With Corticosteroids. Case Reports in Oncological Medicine. 2026;2026(1). doi:10.1155/crom/4222126
BibTeX
@article{Williamson2026,
author = {Williamson, Julie and Pletneva, Maria and Kim, Rebecca G and Bhatia, Roma},
title = {Mitigating Severe Ribociclib‐Hepatotoxicity With Corticosteroids},
journal = {Case Reports in Oncological Medicine},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/crom/4222126}
}
EUVIMED